Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SURGE Therapeutics

Request full access

Seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed

Cambridge, United StatesFounded 2016Biotech & Life Sciences

About SURGE Therapeutics

SURGE Therapeutics is a biotechnology firm focused on improving cancer patient survival through intraoperative immunotherapy. The company has developed an injectable, biodegradable hydrogel that allows for the localized and extended release of immunotherapy drugs directly at the tumor site during surgery. This approach aims to reduce the risk of cancer recurrence by eliminating residual cancer cells left behind after surgical resection, potentially transforming the standard of care for cancer treatment.

The company's business model revolves around the development and clinical validation of its hydrogel-based drug delivery platform. SURGE Therapeutics is currently advancing its lead candidate through clinical trials, having received FDA clearance for a Phase 1/2a study in bladder cancer. The company's target market includes various types of solid tumors where surgery is a primary treatment modality. By focusing on intraoperative application, SURGE serves surgical oncologists and their patients, aiming to turn a curative-intent surgery into a more definitive treatment.

SURGE Therapeutics has secured significant funding, including a $26 million Series A financing round, to support the clinical development of its therapeutic candidates. The company's strategy involves seeking regulatory approval for its products and then commercializing them, likely through partnerships with larger pharmaceutical companies or by building its own commercial infrastructure. The ultimate goal is to establish its intraoperative immunotherapy as a new pillar of cancer care, alongside surgery, chemotherapy, and radiation.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
77.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jul 2023 $32M $128M Pitango Venture Capital · Khosla Ventures · KdT Ventures · Alumni Ventures ↗
SERIES AOther financing Oct 2022 $26M $104M Pitango Venture Capital · 8VC · Cancer Research Institute · Khosla Ventures ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

SURGE Therapeutics website traffic

Latest recorded traffic for SURGE Therapeutics is 1.5K monthly website visits, up 733.3% over the last three months. SURGE Therapeutics's team grew 12.5% over the past year.

Latest monthly visits1.5K 3-month web change+733.3% 1-year team growth+12.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

SURGE Therapeutics in the Cambridge ecosystem

Live from Dealroom

The SURGE Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Venture Kick

Series A10 investors entered at this stage

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States66.7%
🇮🇱 Israel16.7%
🇦🇺 Australia16.7%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about SURGE Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SURGE Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.